European Commission opens antitrust investigation into Sanofi
The European Commission is investigating whether Sanofi breached competition rules through a marketing campaign allegedly disparaging a rival vaccine intended for vulnerable patients.
By Europa Express26 Jun 2026 · 08:00 CETUpdated 26 Jun 2026 · 08:00 CET
Text:
⚡ EXECUTIVE DISPATCH BRIEFVerified · Health
Core Briefing: European Commission opens antitrust investigation into Sanofi
Strategic Context: The European Commission is investigating whether Sanofi breached competition rules through a marketing campaign allegedly disparaging a rival vaccine intended for vulnerable patients.
Fact Checking & Evidence: Documented status is verified across primary accredited European reporting wires and official filings.
Editorial Integrity: Independent coverage adhering to the Europa Express European Press Standards and source verification framework.
AI disclosure: Summarised from a single named source by an AI model with editorial rules; links to the original report.
The European Commission has launched a formal antitrust investigation into pharmaceutical company Sanofi. According to the Commission, the inquiry seeks to determine if the firm violated European Union competition regulations by running a communication campaign that disparaged the only competing influenza vaccine recommended for vulnerable patients with specific risk factors.
The investigation follows a press release issued by the European Commission on 26 June 2026. The regulator is currently assessing whether these promotional activities constitute anticompetitive conduct within the European market.